Latest Working Capital News

Matsa Resources is poised to commence mining at its Devon Pit Gold Mine after securing all regulatory approvals and raising fresh capital. The company targets delivering its final feasibility study in the March 2025 quarter, marking a critical step toward production.

Medical Developments International has posted a robust improvement in operating cash flow and revenue for Q2 FY25, driven by higher demand and pricing for its flagship product Penthrox across Australia and Europe.

Brightstar Resources has consolidated its position as a rising gold producer with key acquisitions expanding its resource base beyond 3 million ounces and the commencement of ore haulage under a new processing agreement. The company’s December quarter report outlines a robust production growth strategy supported by a $30 million capital raise and ongoing exploration success.

SRJ Technologies reported a remarkable 178% increase in Q4 FY24 cash receipts, driven by strong contract activity and strategic partnerships, including a key Middle East market entry. Despite some project delays, the company remains confident in its growth trajectory for FY25.

Strike Energy has obtained $162 million in credit approval from Macquarie Bank, advancing its $217 million financing package to refinance debt and develop the South Erregulla Power Project.

European Lithium Limited has made significant strides in Q4 2024, acquiring the Leinster Lithium Project in Ireland and reporting promising high-grade rare earth results from its Greenland drilling program.

Titan Minerals Limited has entered an underwriting agreement with CPS Capital Group to cover a $2.8 million options shortfall, ensuring funding for its Dynasty Gold Project and working capital needs.

High Peak Royalties has fully repaid its US$750,000 financing facility with Macquarie Bank, removing all associated securities and guarantees. The company signals confidence in its near-term liquidity and operational funding.

KneoMedia reports a successful quarter marked by significant capital raises and expanding deployments of its KneoScience platform across New York City schools, positioning the company for sustained revenue growth.

DXN Limited reported a robust 58.1% revenue increase to $4.8 million in Q2 FY25, underpinned by strategic capital raising and new product innovation targeting AI infrastructure. The company is advancing key mining and telecom projects while streamlining operations to support its ambitious $16 million revenue guidance for FY25.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.

IXUP Limited reports strong sales momentum driven by its largest-ever contract with iGaming Ontario, alongside strategic cost reductions and a clear path to positive cash flow by late 2025.